News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Targeted Therapy Adds Benefit to Erlotinib in Some Patients with Advanced Lung Cancer, Sarah Cannon Research Institute Study


10/11/2010 6:54:10 AM

EurekAlert! -- A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

Read at EurekAlert!
Read at News Release
Read at ScienceDaily


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES